Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01374490 | Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea | PHASE3 | COMPLETED | 250 | — | — | Jun 7, 2011 | Oct 31, 2012 | Aug 31, 2020 | 21 | United States |
| Arm | Type | Description |
|---|---|---|
| Crofelemer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Crofelemer | DRUG | Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer. |
Inclusion Criteria: * Male or female ≥ 18 years old * History of HIV-1 infection * On an antiretroviral therapeutic regimen for treatment of HIV-1 disease and associated conditions (including prophylactic antibiotics for Pneumocystis jirovecii or infection) for at least 4 weeks prior to screening *...